Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

The new COVID-19 vaccine rolled out across the country last month, giving people access to the most recent versions of the Moderna, Pfizer ... and these work a little differently.

A path to quickly reviving Pfizer’s fortunes isn’t straightforward, some analysts say. “We do not see low-hanging ... race to develop the coronavirus vaccine. Pfizer won the gratitude ...

New COVID-19 strains are emerging and with it the need for updated vaccines to protect people from the virus. So how do ...

Platelets are cells that help your blood clot, and it was so unusual to see blood clots combined with low platelet levels, ...

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

With Pfizer’s stock down sharply, an activist investor is pushing for something new from the CEO who spurred the company to ...

Michela Tindera But despite losing Read and D’Amelio’s support, Starboard is still pushing ahead with its campaign. Yesterday, October 22nd, at an activist investor conference in New York, Starboard ...

The lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 pandemic.

As the COVID virus continues to evolve, experts in respiratory diseases recommend that everyone ages 6 months and older ...